Why the study?
Angiosarcomas are aggressive cancers of endothelial origin characterized by chemotherapy resistance and dismal prognosis, creating a need to identify transcriptomic biomarkers of chemoresistance.
Is SPP1 overexpression associated with chemoresistance and poor prognosis in patients with angiosarcoma?
Population
72 cases of Asian angiosarcomas, including 35 treated with palliative chemotherapy
Comparison
Chemoresistant cohort vs responsive disease, and tumor tissues vs adjacent normal compartments
Design
Transcriptomic biomarker study integrating profiling, immunohistochemistry, and cell line assays
Authors
Loading...
SPP1 overexpression may flag chemoresistance risk in angiosarcoma; hypothesis-generating for prospective biomarker validation.
Is SPP1 overexpression associated with chemoresistance and poor prognosis in patients with angiosarcoma?
SPP1 overexpression is identified as a potential biomarker for chemoresistance and poor prognosis in Asian patients with angiosarcoma.
Khor et al. (2024) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: